Your browser is no longer supported. Please, upgrade your browser.
We’ve released a new Beta version of our Futures section! Try it now. We look forward to your feedback! ×
FLDM [NASD]
Fluidigm Corporation
Index- P/E- EPS (ttm)-1.91 Insider Own0.10% Shs Outstand28.37M Perf Week-3.41%
Market Cap1.20B Forward P/E- EPS next Y-1.10 Insider Trans-88.25% Shs Float27.94M Perf Month2.02%
Income-52.80M PEG- EPS next Q-0.44 Inst Own97.30% Short Float10.77% Perf Quarter13.43%
Sales116.50M P/S10.34 EPS this Y-192.30% Inst Trans0.13% Short Ratio14.81 Perf Half Y59.36%
Book/sh5.33 P/B7.97 EPS next Y23.10% ROA-12.70% Target Price49.67 Perf Year12.35%
Cash/sh4.06 P/C10.45 EPS next 5Y33.00% ROE-33.30% 52W Range21.71 - 46.38 Perf YTD25.91%
Dividend- P/FCF- EPS past 5Y29.60% ROI-13.60% 52W High-8.43% Beta1.02
Dividend %- Quick Ratio4.80 Sales past 5Y35.60% Gross Margin63.30% 52W Low95.62% ATR1.82
Employees474 Current Ratio5.30 Sales Q/Q60.30% Oper. Margin-35.30% RSI (14)49.12 Volatility4.15% 4.52%
OptionableYes Debt/Eq1.30 EPS Q/Q-116.70% Profit Margin-45.30% Rel Volume1.11 Prev Close43.20
ShortableYes LT Debt/Eq1.30 EarningsMay 04 AMC Payout- Avg Volume203.19K Price42.47
Recom1.80 SMA200.64% SMA501.15% SMA20029.71% Volume225,280 Change-1.69%
May-06-14Reiterated Maxim Group Buy $65 → $52
Apr-23-14Upgrade Mizuho Neutral → Buy $43 → $50
Mar-21-14Reiterated Maxim Group Buy $52 → $65
Feb-03-14Reiterated Oppenheimer Outperform $46 → $52
Jan-14-14Reiterated Mizuho Neutral $30 → $43
Dec-18-13Reiterated Maxim Group Buy $33 → $42
Oct-31-13Reiterated Mizuho Neutral $19 → $30
Oct-31-13Reiterated Maxim Group Buy $26 → $33
Aug-02-13Reiterated Mizuho Neutral $17 → $19
Aug-02-13Reiterated Maxim Group Buy $21 → $23
Jun-27-13Initiated Maxim Group Buy $21
Oct-09-12Downgrade Mizuho Buy → Neutral $17
Aug-31-12Initiated Mizuho Buy $17
Jun-27-12Initiated Cantor Fitzgerald Buy $17
Feb-15-12Reiterated Deutsche Bank Buy $16 → $19.50
Oct-05-11Initiated Oppenheimer Outperform $19
Mar-23-11Initiated Deutsche Bank Buy $19
Apr-22-15 12:10PM  Thermo Fisher Q1 Earnings Top, Revenues Lag Estimates - Analyst Blog
Apr-16-15 11:50AM  Inogen Gains despite Further Delay in Form 10-K Filing - Analyst Blog
11:20AM  Thoratec Hits 52-Week High on Favorable Developments - Analyst Blog
Apr-14-15 01:10PM  Masimo to Launch Patient SafetyNet System with Iris, MyView - Analyst Blog
Apr-13-15 01:00PM  DexCom Launches CGM App on Apple Watch; Shares Rise - Analyst Blog
Apr-10-15 10:50AM  AngioDynamics Lags Earnings on Lower Sales, View Tepid - Analyst Blog
Apr-08-15 04:26PM  FLUIDIGM CORP Files SEC form 8-K, Entry into a Material Definitive Agreement
Apr-07-15 11:40AM  Luminex (LMNX) Launches NxTAG RPP for Respiratory Testing - Analyst Blog
Apr-01-15 12:40PM  Inogen Fails 10-K Deadline; Files Form 12b-25 for Extra Time - Analyst Blog
Mar-30-15 07:00AM  The Best and Worst Medalists of 2015's First Quarter at Morningstar +6.27%
Mar-26-15 06:47PM  Inogen's Texas Facility Ready, Costs Likely to Scale Down - Analyst Blog
Mar-25-15 11:10AM  Abiomed Attains New 52-Week High on Impella 2.5 Approval - Analyst Blog -5.84%
Mar-24-15 12:50PM  Abiomed's Impella 2.5 FDA-Approved for PCI Procedures - Analyst Blog
Mar-13-15 10:00AM  Cantel Medical Beats Q2 Earnings, Provides Positive Outlook - Analyst Blog
Mar-12-15 01:30PM  Inogen (INGN) Postpones Q4 Results; Reiterates 2015 View - Analyst Blog
Mar-05-15 01:04PM  FLUIDIGM CORP Financials
Mar-02-15 11:50AM  Symmetry Surgical Posts Loss in Q4, Revenues Decline Y/Y - Analyst Blog
Feb-28-15 07:08PM  10-K for Fluidigm Corp. at Company Spotlight
Feb-26-15 06:18PM  FLUIDIGM CORP Files SEC form 10-K, Annual Report
Feb-25-15 02:15PM  SNP Trace Panel Proves to Be a High-Throughput, Cost-Effective SNP-Based Platform for Profiling Human Tissue and Cell Lines Business Wire
Feb-24-15 09:00AM  Fluidigm to Present at the 35th Annual Cowen & Company Health Care Conference Business Wire
08:16AM  Teleflex Hits 52-Week High on Strong Q4, Strategic Deals - Analyst Blog
Feb-19-15 09:00AM  Fluidigm Debuts Newest State-of-the-Art Single-Cell System at AGBT Business Wire
Feb-17-15 10:26AM  Abiomed Hits 52-Week High on Solid Q3, Impella RP Approval - Analyst Blog
Feb-12-15 08:59AM  Earnings Estimates Moving Higher for Fluidigm (FLDM): Time to Buy? - Tale of the Tape Zacks
Feb-09-15 09:10AM  Fluidigm Q4 Loss Narrower Than Expected, Revenues Up Y/Y - Analyst Blog Zacks
Feb-05-15 05:39PM  Fluidigm reports 4Q loss AP
05:00PM  Fluidigm Corp Earnings Call scheduled for 5:00 pm ET today CCBN
04:15PM  FLUIDIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:05PM  Science for Life Laboratory Forms Swedish National Center for Single-Cell Biology Business Wire
04:00PM  Fluidigm Reports Q4 and Full Year 2014 Financial Results Business Wire
07:07AM  Q4 2014 Fluidigm Corp Earnings Release - After Market Close CCBN
Jan-30-15 09:15AM  Will Fluidigm (FLDM) Continue to Surge Higher? - Tale of the Tape Zacks
Jan-27-15 09:00AM  Fluidigm to Announce Q4/Full Year 2014 Financial Results and Host Conference Call for Investors Business Wire
Jan-21-15 09:25AM  Strength Seen in Fluidigm (FLDM): Stock Moves 9.8% Higher - Tale of the Tape Zacks
Jan-20-15 02:30PM  Street Talk: INTC, HD, MU, JKHY & FLDM CNBC +9.82%
Jan-14-15 05:30PM  Fluidigm's Preliminary Q4 Revenues Up Y/Y, Outlook Positive - Analyst Blog Zacks
Jan-13-15 05:03PM  FLUIDIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:00PM  Fluidigm Announces Preliminary Fourth Quarter 2014 Revenue and Issues 2015 Revenue Guidance Business Wire
Jan-05-15 09:00AM  Fluidigm to Present at the 33rd Annual J.P. Morgan Healthcare Conference Business Wire
Dec-29-14 09:00AM  New Single-Cell Whole Genome Sequencing Workflow Allows Discovery of Novel Cellular Heterogeneity Business Wire
Dec-17-14 06:24AM  Making Single-Cell Biology Work Business Wire +5.87%
Dec-15-14 07:03AM  Synergetics USA (SURG) Jumps: Stock Adds 9.1% in Session Zacks
Dec-11-14 06:15AM  Novadaq Technologies Inc. (NVDQ) in Focus: Stock Soars 17.1% Zacks
Dec-10-14 01:30PM  Cyberonics Posts Positive Epilepsy Device Data, Shares Up Zacks
Dec-05-14 01:40PM  Hologic (HOLX) Turns Around: Should You Invest Now? Zacks
Dec-03-14 05:10PM  Thoratec Completes Enrollment for HeartMate III CE Mark Trial Zacks
Nov-28-14 02:50PM  Edwards Lifesciences Strong on Robust Q3, Raised Outlook Zacks
Nov-25-14 01:50PM  Cepheid Gets FDA Clearance for Xpert Flu/RSV XC Test Zacks
Nov-24-14 01:30PM  Fluidigm to Present at the Piper Jaffray 26th Annual Healthcare Conference Business Wire
Nov-19-14 04:15PM  Fluidigm's (FLDM) New Workflow to Allow High Throughput Zacks
Nov-18-14 03:50PM  Fluidigm (FLDM) Now a Strong Buy on Key Product Releases Zacks
12:00PM  Fluidigm Announces New High Throughput Workflow for Single-Cell mRNA Sequencing Business Wire
Nov-17-14 09:13AM  Fluidigm (FLDM) Upgraded From Sell to Hold at TheStreet
Nov-14-14 03:01AM  Genome testing is now easy, fast and pretty at Engadget
Nov-11-14 09:10AM  New Cancer Detection Technique Has Enormous Potential for Life Science Stocks at 24/7 Wall St.
Nov-10-14 09:00AM  Fluidigm Ushers in a New Era of Customer Experience Business Wire
Nov-08-14 07:07PM  10-Q for Fluidigm Corp. Company Spotlight
Nov-06-14 04:43PM  FLUIDIGM CORP Files SEC form 10-Q, Quarterly Report EDGAR Online
01:20PM  Teleflex Beats on Q3 Earnings & Revenues, Outlook Raised Zacks
Nov-05-14 01:00PM  CryoLife Q3 Earnings Fall, Revenues Rise Y/Y; Shares Tank Zacks
Nov-04-14 02:10PM  Mindray Medical Q3 Earnings in Line, 2014 View Lowered Zacks
11:05AM  Becton, Dickinson (BDX) Beats Q4 Earnings, Revenues Zacks
Oct-30-14 06:46PM  Fluidigm posts 3Q loss AP
04:24PM  FLUIDIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:00PM  Fluidigm Reports Q3 2014 Results Business Wire
07:07AM  Q3 2014 Fluidigm Corp Earnings Release - After Market Close CCBN
Oct-22-14 09:39AM  Will Fluidigm (FLDM) Continue to Surge Higher? Zacks
Oct-21-14 09:00AM  Fluidigm to Announce Q3 2014 Financial Results and Host Conference Call for Investors Business Wire
Oct-02-14 09:00AM  Fluidigm Redefines Single-Cell Whole Exome Sequencing Business Wire
Sep-25-14 02:00PM  Stanford Researchers Use Single-Cell Mass Cytometry to Predict Recovery Time from Surgery Business Wire
Sep-19-14 07:07AM  FLUIDIGM CORP Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online -6.30%
Sep-16-14 04:00PM  Fluidigms New JunoTM System Shatters Barriers For SNP Genotyping Business Wire
Sep-03-14 07:28AM  Fluidigm Corp. (FLDM) Worth Watching: Stock Up 5.1% Zacks
Sep-02-14 01:00PM  Fluidigm to Present at the Morgan Stanley Global Healthcare Conference Business Wire +5.07%
Aug-06-14 09:00AM  UCSF/Fluidigm Paper Proves Shallow Sequencing of Related Single Cells Sufficient to Harvest Meaningful Biological Information Business Wire
Aug-04-14 03:57PM  FLUIDIGM CORP Files SEC form 10-Q, Quarterly Report EDGAR Online
Jul-31-14 04:17PM  FLUIDIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:05PM  Fluidigm Reports Q2 2014 Results Business Wire
04:00PM  Fluidigm Announces Early Access Program for New Imaging Mass Cytometry Platform Business Wire
07:07AM  Q2 2014 Fluidigm Corp Earnings Release - After Market Close CCBN
Jul-23-14 09:00AM  Fluidigm to Announce Q2 2014 Financial Results and Host Conference Call for Investors Business Wire +5.08%
Jul-10-14 10:59AM  Fluidigm expected to report strong quarter at Piper Jaffray theflyonthewall.com
Jun-30-14 09:00AM  Single-Cell mRNA Sequencing Helps Reveal the Role of Precocious Dendritic Cells in Inflammatory Response Business Wire
Jun-19-14 09:00AM  Fluidigm Accelerates Single-Cell Science with the New C1 Open App Program Business Wire
Jun-10-14 04:00PM  FLUIDIGM CORP Files SEC form 8-K, Entry into a Material Definitive Agreement EDGAR Online
Jun-03-14 09:00AM  Fluidigm Ships FLEXsixTM Integrated Fluidic Circuits to Genotyping and Gene Expression Customers Business Wire
May-28-14 04:13PM  FLUIDIGM CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
May-12-14 05:07PM  FLUIDIGM CORP Files SEC form 10-Q, Quarterly Report EDGAR Online
May-06-14 09:00AM  Fluidigm to Present at the Bank of America Merrill Lynch 2014 Healthcare Conference Business Wire -16.06%
May-05-14 11:22PM  Fluidigm's (FLDM) CEO Gajus Worthington on Q1 2014 Results - Earnings Call Transcript at Seeking Alpha
04:55PM  Fluidigm Corporation Discusses Q1 2014 Results (Webcast) at Seeking Alpha
04:49PM  FLUIDIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:26PM  Fluidigm Reports Q1 2014 Results Business Wire
07:07AM  Q1 2014 Fluidigm Corp Earnings Release - After Market Close CCBN
Apr-29-14 10:49AM  Fluidigm: Unique Investing Opportunity In Single-Cell Genomics at Seeking Alpha
Apr-23-14 08:00PM  Fluidigm to Announce Q1 2014 Financial Results and Host Conference Call for Investors Business Wire
05:48AM  Fluidigm upgraded by Mizuho Briefing.com
Apr-14-14 12:02PM  Why Fluidigm (FLDM) Stock Is Up Today at TheStreet
07:04AM  Fluidigm upgraded to Outperform from Market Perform at Leerink theflyonthewall.com
Fluidigm Corporation creates, manufactures, and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics. It provides various preparatory instruments, including C1 single-cell auto prep system, a sample preparation system that isolates, processes, and profiles individual cells for genomic analysis; and access array systems that enables automated polymerase chain reaction (PCR)-based target enrichment, barcoding, and tagging of resequencing libraries and facilitates parallel amplification. The company also offers analytical instruments comprising Biomark HD system, a PCR analytical instrument for gene expression analysis, single-cell targeted gene expression analysis, microRNA analysis, single nucleotide polymorphism (SNP) genotyping, and digital PCR; EP1 system that performs high-throughput SNP genotyping and end-point digital PCR; and CyTOF 2 system, a mass cytometry instrument that performs single-cell protein analysis by analyzing cells labeled with a panel of reagents conjugated to stable metal isotopes. In addition, it provides integrated fluidic circuits (IFCs), such as C1, access array, dynamic array, digital array, and flex six IFCs; assays and reagents consisting of Delta Gene and SNP type assays, access array target-specific primers, and Maxpar Reagents. Further, the company's products include juno systems and IFCs, callisto systems and IFCs, polaris systems and IFCs, and C1 mRNA Sequencing IFCs. It serves academic institutions; clinical laboratories; and pharmaceutical, biotechnology, and agricultural biotechnology companies. The company distributes its products through direct sales force and support organizations, distributors, or sales agents. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Yow Mai ChanSee RemarksApr 20Option Exercise15.4915,300236,99716,816Apr 22 05:14 PM
Yow Mai ChanSee RemarksApr 20Sale44.7315,300684,3061,516Apr 22 05:14 PM
Yow Mai ChanSee RemarksApr 17Option Exercise15.494,70072,8036,216Apr 21 05:12 PM
Smith William MaxwellEVP, LEGAL AFFAIRS & GCApr 17Option Exercise4.453,00013,3383,922Apr 21 05:15 PM
Yow Mai ChanSee RemarksApr 17Sale44.044,700206,9881,516Apr 21 05:12 PM
Smith William MaxwellEVP, LEGAL AFFAIRS & GCApr 17Sale43.053,000129,163922Apr 21 05:15 PM
Yow Mai ChanSee RemarksApr 08Option Exercise15.2630,000457,70531,516Apr 09 08:45 PM
Yow Mai ChanSee RemarksApr 08Sale42.6730,0001,280,0001,516Apr 09 08:45 PM
JOG VIKRAMCHIEF FINANCIAL OFFICERApr 07Option Exercise14.603,95057,6704,894Apr 09 07:37 PM
JOG VIKRAMCHIEF FINANCIAL OFFICERApr 07Sale40.813,950161,192944Apr 09 07:37 PM
JONES ROBERT CEVP, RESEARCH & DEVELOPMENTApr 01Option Exercise14.603,00043,8003,947Apr 03 07:15 PM
Worthington Gajus VincentPRESIDENT & CEOApr 01Option Exercise4.456,00026,67710,394Apr 03 07:15 PM
JONES ROBERT CEVP, RESEARCH & DEVELOPMENTApr 01Sale41.633,000124,890947Apr 03 07:15 PM
Worthington Gajus VincentPRESIDENT & CEOApr 01Sale40.026,000240,1004,394Apr 03 07:15 PM
Smith William MaxwellEVP, LEGAL AFFAIRS & GCMar 16Option Exercise4.163,00012,4933,922Mar 18 08:08 PM
Smith William MaxwellEVP, LEGAL AFFAIRS & GCMar 16Sale40.873,000122,610922Mar 18 08:08 PM
JOG VIKRAMCHIEF FINANCIAL OFFICERMar 09Option Exercise14.603,95057,6704,894Mar 11 08:01 PM
JOG VIKRAMCHIEF FINANCIAL OFFICERMar 09Sale41.483,950163,842944Mar 11 08:01 PM
Worthington Gajus VincentPRESIDENT & CEOMar 02Option Exercise4.456,00026,67710,394Mar 04 08:03 PM
JONES ROBERT CEVP, RESEARCH & DEVELOPMENTMar 02Option Exercise14.603,00043,8003,947Mar 04 08:04 PM
Worthington Gajus VincentPRESIDENT & CEOMar 02Sale43.776,000262,6464,394Mar 04 08:03 PM
JONES EVAN/ FADirectorMar 02Sale44.157,500331,13364,451Mar 04 08:05 PM
JONES ROBERT CEVP, RESEARCH & DEVELOPMENTMar 02Sale43.783,000131,340947Mar 04 08:04 PM
COLELLA SAMUEL DDirectorFeb 20Option Exercise4.455,70025,34325,373Feb 23 06:15 PM
COLELLA SAMUEL DDirectorFeb 20Sale38.925,700221,84919,673Feb 23 06:15 PM
COLELLA SAMUEL DDirectorFeb 19Option Exercise11.8938,840461,96158,513Feb 23 06:15 PM
COLELLA SAMUEL DDirectorFeb 19Sale38.9738,8401,513,72719,673Feb 23 06:15 PM
Smith William MaxwellEVP, LEGAL AFFAIRS & GCFeb 18Option Exercise4.083,00012,2483,726Feb 20 06:11 PM
COLELLA SAMUEL DDirectorFeb 18Option Exercise16.008,800140,80028,473Feb 20 06:12 PM
COLELLA SAMUEL DDirectorFeb 18Sale38.718,800340,65919,673Feb 20 06:12 PM
Smith William MaxwellEVP, LEGAL AFFAIRS & GCFeb 18Sale38.533,000115,590726Feb 20 06:11 PM
JONES ROBERT CEVP, RESEARCH & DEVELOPMENTFeb 11Option Exercise14.604,90071,5405,626Feb 13 07:41 PM
JONES ROBERT CEVP, RESEARCH & DEVELOPMENTFeb 11Sale37.624,900184,329726Feb 13 07:41 PM
JOG VIKRAMCHIEF FINANCIAL OFFICERFeb 10Option Exercise14.983,95059,1852,974Feb 12 07:54 PM
JOG VIKRAMCHIEF FINANCIAL OFFICERFeb 10Sale37.743,950149,065726Feb 12 07:54 PM
Worthington Gajus VincentPRESIDENT & CEOFeb 02Option Exercise4.456,00026,6779,380Feb 04 07:22 PM
Worthington Gajus VincentPRESIDENT & CEOFeb 02Sale38.156,000228,9113,380Feb 04 07:22 PM
Worthington Gajus VincentPRESIDENT & CEOJan 02Option Exercise4.456,00026,6779,380Jan 06 08:15 PM
Worthington Gajus VincentPRESIDENT & CEOJan 02Sale33.376,000200,2123,380Jan 06 08:15 PM
Smith William MaxwellEVP, LEGAL AFFAIRS & GCDec 15Option Exercise4.083,00012,2483,726Dec 17 08:00 PM
Smith William MaxwellEVP, LEGAL AFFAIRS & GCDec 15Sale27.203,00081,600726Dec 17 08:00 PM
JONES EVAN/ FADirectorDec 12Sale27.563,35292,36971,951Dec 15 08:00 PM
JONES EVAN/ FADirectorDec 11Sale27.365,000136,80175,303Dec 15 08:00 PM
JONES EVAN/ FADirectorDec 09Sale28.032,33665,47580,303Dec 10 08:01 PM
JOG VIKRAMCHIEF FINANCIAL OFFICERDec 08Option Exercise15.493,95061,1864,676Dec 10 08:00 PM
JONES EVAN/ FADirectorDec 08Sale29.061,00029,06082,639Dec 10 08:01 PM
JOG VIKRAMCHIEF FINANCIAL OFFICERDec 08Sale29.073,950114,827726Dec 10 08:00 PM
Worthington Gajus VincentPRESIDENT & CEODec 01Option Exercise4.456,00026,6779,380Dec 03 10:06 AM
Worthington Gajus VincentPRESIDENT & CEODec 01Sale30.036,000180,1893,380Dec 03 10:06 AM
Smith William MaxwellEVP, LEGAL AFFAIRS & GCNov 17Option Exercise4.423,00013,2543,508Nov 19 07:59 PM
Smith William MaxwellEVP, LEGAL AFFAIRS & GCNov 17Sale29.523,00088,573508Nov 19 07:59 PM
JONES EVAN/ FADirectorNov 12Sale29.555,000147,72983,639Nov 14 07:20 PM
JONES EVAN/ FADirectorNov 11Sale28.8010,000287,96888,639Nov 13 09:29 PM
JOG VIKRAMCHIEF FINANCIAL OFFICERNov 07Option Exercise16.343,95064,5573,227Nov 12 06:44 PM
JOG VIKRAMCHIEF FINANCIAL OFFICERNov 07Sale29.453,950116,337508Nov 12 06:44 PM
Worthington Gajus VincentPRESIDENT & CEOOct 16Sale25.015,159129,00633,029Oct 20 06:42 PM
Smith William MaxwellEVP, LEGAL AFFAIRS & GCOct 15Option Exercise4.453,00013,3383,508Oct 17 06:32 PM
Smith William MaxwellEVP, LEGAL AFFAIRS & GCOct 15Sale22.323,00066,960508Oct 17 06:32 PM
JOG VIKRAMCHIEF FINANCIAL OFFICEROct 07Option Exercise16.733,95066,0844,458Oct 09 06:18 PM
JOG VIKRAMCHIEF FINANCIAL OFFICEROct 07Sale22.653,95089,468508Oct 09 06:18 PM
Smith William MaxwellEVP, LEGAL AFFAIRS & GCSep 15Option Exercise4.453,00013,3383,508Sep 17 06:38 PM
Smith William MaxwellEVP, LEGAL AFFAIRS & GCSep 15Sale30.833,00092,490508Sep 17 06:38 PM
JOG VIKRAMCHIEF FINANCIAL OFFICERSep 08Option Exercise16.733,95066,0844,458Sep 10 07:56 PM
JOG VIKRAMCHIEF FINANCIAL OFFICERSep 08Sale28.573,950112,852508Sep 10 07:56 PM
Smith William MaxwellEVP, LEGAL AFFAIRS & GCAug 15Option Exercise3.413,00010,2293,290Aug 19 06:54 PM
Smith William MaxwellEVP, LEGAL AFFAIRS & GCAug 15Sale27.853,00083,550290Aug 19 06:54 PM
JOG VIKRAMCHIEF FINANCIAL OFFICERAug 07Option Exercise15.643,73358,3764,023Aug 11 07:07 PM
JOG VIKRAMCHIEF FINANCIAL OFFICERAug 07Sale26.343,73398,327290Aug 11 07:07 PM
Worthington Gajus VincentPRESIDENT & CEOAug 06Sale26.536,000159,16344,188Aug 08 07:44 PM
Smith William MaxwellEVP, LEGAL AFFAIRS & GCJul 15Option Exercise3.393,00010,1723,290Jul 17 06:40 PM
Smith William MaxwellEVP, LEGAL AFFAIRS & GCJul 15Sale31.983,00095,940290Jul 17 06:40 PM
JOG VIKRAMCHIEF FINANCIAL OFFICERJul 07Option Exercise15.495,42784,0645,717Jul 09 06:36 PM
JOG VIKRAMCHIEF FINANCIAL OFFICERJul 07Sale30.615,427166,125290Jul 09 06:36 PM
Worthington Gajus VincentPRESIDENT & CEOJul 01Sale29.726,000178,32850,188Jul 03 06:16 PM
Smith William MaxwellEVP, LEGAL AFFAIRS & GCJun 16Option Exercise3.393,00010,1723,290Jun 18 08:25 PM
Smith William MaxwellEVP, LEGAL AFFAIRS & GCJun 16Sale27.643,00082,920290Jun 18 08:25 PM
JOG VIKRAMCHIEF FINANCIAL OFFICERJun 09Option Exercise15.493,95061,1864,240Jun 11 08:24 PM
JOG VIKRAMCHIEF FINANCIAL OFFICERJun 09Sale26.963,950106,492290Jun 11 08:24 PM
Worthington Gajus VincentPRESIDENT & CEOJun 02Sale26.556,000159,29156,188Jun 04 07:05 PM
Smith William MaxwellEVP, LEGAL AFFAIRS & GCMay 15Option Exercise3.393,00010,1723,000May 19 07:10 PM
Smith William MaxwellEVP, LEGAL AFFAIRS & GCMay 15Sale28.533,00085,5900May 19 07:10 PM
Worthington Gajus VincentPRESIDENT & CEOMay 08Sale32.146,000192,81562,188May 12 07:22 PM